Anti brca2

The staining cells for these analyses was performed as previously described [15 (link)]. Anti-Ki67 (1:500, Zhongshan Bio-Tech, Beijing, China) and anti-BRCA2 (1:100, Cell Signaling Technology) antibodies were used for these assays.

Carfilzomib was obtained from Selleck Chemicals. Pan-histone deacetylase (HDAC) inhibitors panobinostat (PS) and vorinostat (VS) were obtained from Novartis Pharmaceuticals (East Hanover, NJ) and Selleck Chemicals, respectively. All drugs were prepared as 10 mM stocks in 100% DMSO and stored in small aliquots at −80°C to prevent multiple free thaw cycles. Anti-phosphorylated (p)-ATR (S428), anti-p-CHK1(S345), anti-α/β tubulin, anti-DNA-PKcs, anti-acetyl histone H3 (K9/K14), anti-histone H3, anti-RAD52, anti-BRCA2 and anti-acetyl lysine antibodies were purchased from Cell Signaling Technology (Berverly, MA). Anti-hsp90α and anti-hsp70 antibody was purchased from Enzo Biosciences (Plymouth Meeting, PA). Anti-BRCA1 and anti-γ-H2AX antibodies were obtained from Millipore (Billerica, MA). Anti-CHK1, anti-ATR, anti-HDAC1, anti-HDAC2, and anti-HDAC3 antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-β-actin, anti-FLAG, anti-acetylated α-tubulin and anti-GFP antibodies and short hairpin RNAs against HDAC1, HDAC2 and HDAC3 were purchased from Sigma-Aldrich (St. Louis, MO). Acetylated-K69 hsp90 (Ac-K69 hsp90) antibody was previously described [24 (link)]. Anti-c-RAF antibody was purchased from BD Transduction Labs (San Jose, CA).